Indonesian Political, Business & Finance News

Danantara Reveals Strategy to Improve State-Owned Pharmaceutical Companies' Performance

| Source: CNBC Indonesia Translated from Indonesian | Economy
Danantara Reveals Strategy to Improve State-Owned Pharmaceutical Companies' Performance
Image: CNBC Indonesia

Jakarta, CNBC Indonesia - The Danantara Investment Management Agency (BPI Danantara) continues to pursue transformation across state-owned enterprises (BUMN). This step is being taken by Danantara to improve financial performance and enhance the competitiveness of companies, particularly state-owned pharmaceutical firms.

Chief Operating Officer (COO) of BPI Danantara Dony Oskaria said that the problems faced by state-owned pharmaceutical companies before Danantara’s establishment included factory investments, low utilisation, high debt burdens, and issues with pharmacy networks.

He admitted that when Danantara began its transformation, the condition of PT Kimia Farma Tbk was concerning. The company’s financial position was unhealthy due to investment decisions that did not consider return on investment.

‘This was caused by excessive investment. Investment that was not measured by return on investment. They built many large factories with low utilisation. Because the factory investment was so large, there were financing costs through debt and depreciation, causing the company to suffer losses, while utilisation was only 40%,’ Dony said on Squawk Box CNBC Indonesia, Thursday (27/8/2026).

Problems also affected Kimia Farma’s subsidiary, PT Kimia Farma Apotek, which operates more than 1,000 pharmacies. Previously, Kimia Farma Apotek had received investment of Rp 1.5 trillion from the Indonesia Investment Authority (INA) together with a Chinese partner. However, during the verification process, issues emerged with inventory data.

‘In the course of events, the data presented by Kimia Farma Apotek was false. Because the data was false, the investors complained. How was it false? All inventory - you can imagine we have more than 1,000 pharmacies - the data, the stock, was manual and could not be verified. When they carried out verification, the data was all false,’ Dony revealed.

Ultimately, the problem led to a dispute with investors. As a result, Kimia Farma had an obligation to return the investment along with penalties and other costs. Consequently, Danantara pushed for restructuring by replacing management and improving the information technology systems at Kimia Farma Apotek.

In order to rescue Kimia Farma, Danantara also carried out equity injections as well as debt restructuring. These efforts have begun to yield results, as Kimia Farma has recorded a profit this year.

Dony continued that Kimia Farma also faced financial constraints that impacted the reduction in the number of products manufactured. Currently, Kimia Farma only produces 99 pharmaceutical-related products. In addition, Kimia Farma is strengthening the added value of existing products so that its business does not continue to shrink.

‘I said that if this continued, it could cause the company to die slowly. So we carried out an equity injection in the Kimia Farma holding company, and besides the equity injection, we also restructured their debt. As a result of this transformation process, this year Kimia Farma has made a profit. What does that mean? The transformation we carried out fundamentally has brought the company into a good position,’ he explained.

On the other hand, Indofarma’s condition is considered different. The business scale, production capacity, flagship products, as well as the debt and asset condition of Indofarma are deemed no longer strong enough to support the company’s business continuity independently.

Danantara has therefore prepared specific parameters to determine which state-owned enterprises can still be saved and which must be liquidated. Dony said this step is part of the restructuring of thousands of companies within the BUMN environment to make their business structures healthier and more efficient.

More from 27 August 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/danantara-reveals-strategy-to-improve-state-owned-pharmaceutical-companies-performance-1787827961)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/market/20260827170358-17-762865/buka-bukaan-begini-strategi-danantara-poles-kinerja-bumn-farmasi), translated from Indonesian
Print